ABSTRACT
Androgenetic alopecia (AGA) is the most common cause of hair loss, and while topical minoxidil and oral 5-α-reductase inhibitors remain first-line therapies, clinical results are often limited by transepidermal absorption, suboptimal follicular delivery and patient compliance. Tattoo machine–assisted drug delivery, also known as Microinfusion of Medicaments into the Skin (MMP®), is emerging as a useful technique that combines controlled scalp microneedling with direct intradermal deposition of therapeutic agents.
This article describes a combined regenerative technique (CRT) that integrates tattoo machine–assisted infusion of minoxidil sulfate, dutasteride, copper peptides, and platelet-rich plasma with concurrent oral minoxidil and topical finasteride. The biologic rationale, equipment, clinical protocol, and practical considerations are reviewed.
Early clinical experience suggests that this multimodal approach may enhance hair density and shaft thickness while maintaining a favorable safety profile. Tattoo machine–assisted drug delivery represents a promising adjunctive strategy for clinicians seeking to optimize medical management of AGA, though larger controlled studies are needed to further define its role.
- Copyright © 2026 by the International Society of Hair Restoration Surgery
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article.






